NanoXplore Reports First Quarter 2023 Results and Unveils Its 5-year Strategic Plan

NanoXplore Inc. ("NanoXplore" or "the Corporation") (TSX: GRA and OTCQX: NNXPF), a world-leading graphene company, reported today financial results for the first quarter ended September 30, 2022, and unveiled its 5-year strategic plan.

All amounts in this press release are in Canadian dollars, unless otherwise stated.

Q1 HIGHLIGHTS STRATEGIC PLAN HIGHLIGHTS
• Revenues from customers grew 52% to $27.1 million vs Q1-2022
• For Q1-2023, Gross margin was 11.6%, an increase of 860 bps over Q1-2022, and Adjusted EBITDA* totaled -$2 million, an improvement of $1.8 million over Q1-2022
• Total liquidity of $49.1 million as at September 30, 2022, including cash and cash equivalents of $42.8 million
• Total long-term debt of $9 million as at September 30, 2022
• For financial year 2023, NanoXplore is guiding for $110 million in total revenues
• The Corporation intends to increase its capacity 5-fold to reach 20,000 ton/year in graphene and battery materials in 5 years
• The Corporation will expand its Sheet Molding Compound (SMC) forming capacity by investing in an additional 10m-lbs capacity to target the large, growing, and promising lightweighting materials market, using its proprietary GrapheneBlack SMC TM
• The Corporation will actively participate in the energy transition and sustainability megatrends

OVERVIEW

Soroush Nazarpour, President and Chief Executive Officer, stated: "Despite being in a tough macro-environment, we are satisfied with the performance of our business. Our revenues from customers grew 52% and our gross margin continues to expand on a year-on-year basis based on better graphene-enhanced products. Having said that, supply chain challenges reduced our total expected revenue of this quarter and company-wide wage increase that we applied on July 1st, reduced our gross margin. We anticipate to offset the negative impact of supply chain disruption and wage increase with higher graphene sales as our graphene commercialization efforts continues."

Pedro Azevedo, Chief Financial Officer, stated: "I am very excited to share our strategic plan for the next 5 years.  It is a targeted approach in the areas we see the best uses for Graphene and where they will create the most value for our shareholders. I am also very pleased with the progress we have made in our financial performance since last year.  Comparing to Q1-2022, we have made significant improvements to gross margins, improved EBITDA and cut operating cash consumption by over 40% while investing in graphene uses with our partners."

Results of operations may include certain unusual and other items which have been separately disclosed, where appropriate, in order to provide a clear assessment of the underlying Corporation results. In addition to IFRS measures, management uses non-IFRS measures in the Corporation's disclosures that it believes provide the most appropriate basis on which to evaluate the Corporation's results.


A. THREE-MONTH PERIOD


Revenues

Q1-2023 Q1-2022 Variation
$ $ $ %
Revenues from customers 27,147,167 17,830,017 9,317,150 52%
Other income 85,358 988,429 (903,071) (91%)
Total revenues 27,232,525 18,818,446 8,414,079 45%

Revenues from customers increased from $17,830,017 in Q1-2022 to $27,147,167 in Q1-2023. This increase is mainly due to a positive product mix including graphene enhanced products, the acquisition of Canuck in December 2021 and price increases offset by lower fluctuating tooling revenues.

Other income decreased from $988,429 in Q1-2022 to $85,358 in Q1-2023. The decrease is explained by the end of the CEWS program set up by the Canadian Federal government to help businesses deal with the COVID-19 pandemic. The Corporation received nil under this program during Q1-2023 compared to $798,641 in Q1-2022 as the program ended in October 2021.


Adjusted EBITDA*

The adjusted EBITDA improved from -$3,760,406 in Q1-2022 to -$1,977,032 in Q1-2023. The variation is explained as follows:

  • Gross margin on revenues from customers increased by $2,624,033 compared to last year due to higher sales as describe above, improved productivity and cost control; and
  • This was offset by higher administrative expenses (SG&A and R&D) of $736,229 mainly due additional headcounts and higher wages, including higher accrued variable compensation.


B. STRATEGIC PLAN


By leveraging its proven formula and to further extend its market-leading position, NanoXplore is announcing, as part of its strategic plan ("Plan"), a significant increase in its graphene and battery materials capacity, reaching 20,000 tons in 2027 from 4,000 tons currently which represents a five-fold increase. Additionally, as part of the Plan, NanoXplore will invest in a 10M-lbs Sheet Molding Compound (SMC) facility in order to capture the large and growing SMC market which targets lightweighting solutions. Following a long and extensive review of its operations, top-down market analysis, and commercialization potential, the strategic plan lays out a path to accelerated growth in 2026 and beyond.

Soroush Nazarpour, President and Chief Executive Officer, stated: "The new strategic plan lays out a path to accelerated growth in the next few years, following successful completion of our previous five-year strategy. Our strategy is to narrow the scope of our funnel and focus on the highest probability of success and high-volume graphene powder applications. Accordingly, we are announcing a significant increase in our graphene and battery materials production capacity."

The Corporation, in order to accomplish its capacity expansion target, will require an investment of $170 million over the next five years, which the investments will be contingent to certain commercial milestones. This growth investment program will be financed through a combination of cash on hand, grants, debt, and equity, if needed. The capital allocation strategy will have the goal of achieving maximum shareholder value creation. The focus will be on three large, growing, and attractive markets: battery materials, lightweighting composites, and specialty compounds. The investments are as follows:

Assets Capacity Addition Location Commissioning year Potential Annual Revenue
Graphene and Battery Materials 12,000 tons/year Montreal, QC 2025 $100 million
SMC 10M lbs/year Newton, NC 2025 $80 million
Graphene 4,000 tons/year HQ 2026 $40 million


C. OTHER


Additional information about the Corporation, including the Corporation's Management Discussion and Analysis for the three-month periods ended September 30, 2022 and 2021 ("MD&A") and the Corporation's consolidated financial statements for the three-month periods ended September 30, 2022 and 2021 (the "financial statements") can be found at www.nanoxplore.ca .

* Non-IFRS Measures

The financial statements and MD&A were prepared using results and financial information determined under IFRS. However, the Corporation considers certain non-IFRS financial measures as useful additional information in measuring the financial performance and condition of the Corporation. These measures, which the Corporation believes are widely used by investors, securities analysts and other interested parties in evaluating the Corporation's performance, do not have a standardized meaning prescribed by IFRS and therefore may not be comparable to similarly titled measures presented by other publicly traded companies, nor should they be construed as an alternative to financial measures determined in accordance with IFRS. Non-IFRS measures include "Adjusted EBITDA".

WEBCAST

NanoXplore will hold a webcast tomorrow, November 15, 2022, at 8:30 am EST to review its first quarter ended September 30, 2022, results. Soroush Nazarpour, CEO and President of NanoXplore, and Pedro Azevedo, Chief Financial Officer, will host the event. To access the webcast please click on the link https://edge.media-server.com/mmc/p/7j3xvu2s or you can access through our website in the Investors section under Events and Presentations. A replay of this event can be accessed via the above link or on our website. To access the 5-year strategic plan presentation, please visit the Investors section under Events and Presentation at www.nanoxplore.ca .

ABOUT NANOXPLORE

NanoXplore is a graphene company, a manufacturer and supplier of high-volume graphene powder for use in industrial markets. The Corporation provides standard and custom graphene-enhanced plastic and composite products to various customers in transportation, packaging, electronics, and other industrial sectors. NanoXplore is headquartered in Montreal, Quebec with manufacturing facilities in Canada, the United States and Europe.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements and forward-looking information (together, "forward-looking statements") within the meaning of applicable securities laws. All statements, other than statements of historical facts, are forward-looking statements, and subject to risks and uncertainties. All forward-looking statements are based on our beliefs as well as assumptions based on information available at the time the assumption was made and on management's experience and perception of historical trends, current conditions and expected future developments, as well as other factors deemed appropriate in the circumstances. No assurance can be given that these assumptions and expectations will prove to be correct. Forward-looking statements are not facts, but only predications and can generally be identified by the use of statements that include phrases such as "anticipate", "believe", "continue", "could", "estimate", "foresee", "grow", "expect", "plan", "intend", "forecast", "future", "guidance", "may", "predict", "project", "should", "strategy", "target", "will" or similar expressions suggesting future outcomes.

Forward-looking information is not a guarantee of future performance and involves a number of risks and uncertainties. Such forward-looking information necessarily involves known and unknown risks and uncertainties, including the relevant assumptions and risks factors set out in NanoXplore's most recent annual management discussion and analysis filed on SEDAR at www.sedar.com, which may cause NanoXplore's actual results to differ materially from any projections of future results expressed or implied by such forward-looking information. These risks, uncertainties and other factors include, among others, the uncertain and unpredictable condition of global economy, notably as a consequence of the Covid-19 pandemic. Any forward-looking information is made as of the date hereof and, except as required by law, NanoXplore does not undertake any obligation to update or revise any forward–looking statement as a result of new information, subsequent events or otherwise.

Forward-looking statements reflect management's current beliefs, expectations and assumptions and are based on information currently available to management. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the future circumstances, outcomes or results anticipated or implied by such forward-looking statements will occur or that plans, intentions or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve known and unknown risks and uncertainties and other factors that could cause actual results to differ materially from those contemplated by such statements.

No securities regulatory authority has either approved or disapproved the contents of this press release.

For further information, please contact:

Martin Gagné
Director of Investor Relations
martin.gagne@nanoxplore.ca
Tel: 1 438 476 1927


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

GRA:CA,NNXPF
The Conversation (0)
Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Determined maximum tolerated dose (MTD) in Phase 1 monotherapy study of NUV-868; Phase 1b studies of NUV-868 in combination with olaparib or enzalutamide remain ongoing

Received U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug (IND) application for NUV-1511, the first clinical candidate from our novel drug-drug conjugate (DDC) platform

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors

Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Robert Mashal, M.D. to its Board of Directors.

"We are delighted to have Dr. Mashal join our Board of Directors," said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. "Robert is a seasoned biotech industry veteran and his experience as an investor, operator, and medical oncologist will provide us with valuable insights. We look forward to working with Robert to advance Nuvation's pipeline."

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors

Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors

NUV-1511 is the first clinical candidate from the company's novel drug-drug conjugate platform

Company anticipates initiating a Phase 1/2 clinical study of NUV-1511 in 1H 2024

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

NanoXplore Receives TSX Approval for Normal Course Issuer Bid

NanoXplore Inc. (TSX: GRA) ("NanoXplore" or the "Corporation") is pleased to announce that the Toronto Stock Exchange (TSX) has approved the Corporation's request to adopt a normal course issuer bid (NCIB) program, through which NanoXplore may purchase, for cancellation, up to 5,936,205 common shares or approximately 5% of the public float (consisting of 118,724,119 common shares as of November 22, 2023, out of the 169,378,431 common shares issued and outstanding). The Corporation may purchase shares under the NCIB over a period of twelve months commencing on December 1, 2023 and ending November 30, 2024, when the bid expires. NCIB purchases are through the facilities of the TSX and certain Canadian Alternative Trading Systems and the price for any repurchased shares will be the prevailing market price at the time of the acquisition.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

NanoXplore Unveils a Large-Scale Dry Process for Manufacturing of Graphene: An Improvement for Cost Competitiveness and Scalability

NanoXplore Inc. ("NanoXplore" or "the Corporation") (TSX: GRA and OTCQX: NNXPF), a world-leading graphene company, proudly announces an interesting achievement in graphite exfoliation with the successful development of a novel dry graphene manufacturing process.

The dry process centers on an advanced exfoliation technology with innovative media that enables high yield exfoliation without the introduction of impurities.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

NanoXplore Reports Results for its Q1-2024

NanoXplore Inc. ("NanoXplore" or "the Corporation") (TSX: GRA and OTCQX: NNXPF), a world-leading graphene company, reported today financial results for the three-month period ended September 30, 2023.

All amounts in this press release are in Canadian dollars, unless otherwise stated.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×